The global Population Screening Market size is expected to reach USD 38.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.36% from 2023 to 2030. The growth of the market is attributed to the increasing prevalence of diseases, the growing geriatric population, and increasing investment in population screening tests. Moreover, the market is expected to be driven significantly by increasing technological advancements and developments in these tests.
An
increase in the prevalence of cardiovascular diseases is expected to boost
segment growth. According to the WHO, 17.7 million people die annually due to
cardiovascular diseases, which is 31.0% of the total deaths occurring
worldwide. Cardiovascular diseases are the leading cause of mortality and
morbidity in the U.S. They are among the main causes of death globally, and
hypertension & its pathological adverse effects pose a significant risk for
other cardiac diseases, such as heart failure & stroke. There are multiple
screening programs available for material fibrillation globally that aim to
reduce the mortality rate. Identifying early-stage hypertension and other CVDs
is of high significance in predicting & preventing major mortality &
morbidity related to these diseases.
The
growing prevalence of rare genetic diseases such as Spinal Muscular Atrophy
(SMA) disorders and increased spending on population screening are among the
major factors for the dominance of the market. According to the National
Organization for Rare Disorders (NORD), SMA affects almost one in 10,000 people
globally. In addition, according to SMA Canada, approximately 700 people were
living with this condition in Canada as of July 2022. For instance, the CDC
released the Recommended Uniform Screening Panel (RUSP) to states under its
statewide universal newborn programs for the early identification of children
with SMA. Thus, such initiatives are undertaken by governments to screen the
population, thereby supporting the growth of the population screening market.
Players
in the market adopt the strategy of product launches to strengthen their
product portfolio and offer diverse, technologically advanced, & innovative
population screening products to patients. Several market players engage in
mergers & acquisitions to strengthen their market position. This strategy
enables companies to boost their capabilities, expand product portfolios, and
improve competencies. For instance, in August 2022, Thermo Fisher Scientific,
Inc., launched an HIV-1 genotyping kit to identify the genetic mutations that
resist Antiretroviral Therapeutics (ART). This kit was intended only for
research purposes.
Related Press
Release@ Population
Screening Market Report
List of Key Players in Population Screening Market
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- Quest Diagnostics
- Illumina, Inc.
- ARUP Laboratories
- Novogene Co., Ltd.
- LGC Limited
- Gene by Gene, Ltd.
Population Screening Market Report Highlights
- The nation
segment held a dominant share of the market in 2022 owing to the
effectiveness and precision offered by CTCs in the detection of cancer
- The premium
segment is projected to grow at the fastest rate over the forecast period
owing to the increasing dominance of private screening programs
- The female
segment is the highest revenue-generating segment in 2022 owing to the
increasing number of tests being performed by females
- North
America dominated the population screening market in 2022, which is
attributed to preventive measures undertaken by governments to stop the
progression of diseases
Population Screening Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2023 |
USD 25,715.15 million |
|
Revenue forecast in 2030 |
USD 38.2 billion |
|
Growth rate |
CAGR of 5.36% from 2023 to 2030 |
|
Base year for estimation |
2022 |
|
Historical data |
2018 - 2021 |
|
Forecast period |
2023 - 2030 |
Related Reports@
Cellular Health Screening Market
Population Screening Market Segmentation
Grand
View Research has segmented the global population screening market based on
geography, product, business, gender, type, age, and region:
Population Screening Geography Outlook (Revenue, USD
Million, 2018 - 2030)
- Nation
- State
Population Screening Product Outlook (Revenue, USD
Million, 2018 - 2030)
- Hardware
Equipment (Instrument, Kits, Chips)
- Testing /
Lab (Services)
- Analytics /
Interpretation (Personalization And Interpretation)
Population Screening Business Outlook (Revenue, USD
Million, 2018 - 2030)
- Hospitals
- Research
Institutes
- Diagnostic
Labs
Population Screening Gender Outlook (Revenue, USD
Million, 2018 - 2030)
- Male
- Female
Population Screening Type Outlook (Revenue, USD
Million, 2018 - 2030)
- Mass
- Premium
Population Screening Age Outlook (Revenue, USD
Million, 2018 - 2030)
- Ages <15
- 15-65
- Ages 65+
Population Screening Regional Outlook (Revenue, USD
Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment